Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure

Reviews in Cardiovascular Medicine

Volumn 5, Issue 1, 2004, Pages 16-25

  McCullough, Peter A ^a   Joseph, Kuncheria ^b   Mathur, Vandana S ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b Bon Secours Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B type natriuretic peptide; Chronic kidney disease; Congestive heart failure; Nesiritide; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; MILRINONE; NESIRITIDE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; SPIRONOLACTONE; TORASEMIDE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HORMONAL REGULATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LUNG CAPILLARY PRESSURE; LUNG PRESSURE; NATRIURESIS; REVIEW; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; COMORBIDITY; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; REGIONAL BLOOD FLOW;

EID: 1542712459     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11:1277-1285.
2. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003; 41:11-17.
3. Dzau VJ. Renin-anglotensin system and renal circulation in clinical congestive heart failure. Kidney Int Suppl. 1987;20:S203-S209.
4. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999; 106:90-96.
5. Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis. 2001; 37:677-688.
6. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: Cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci, 2003;326:15-24.
7. Lai KN, Leung JC, Yandle TG, et al. Gene expression and synthesis of natriuretic peptides by cultured human glomerular cells. J Hypertension. 1999;17:575-583.
8. Chen HH, Burnett JC. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999; 111:406-416.
9. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Card. 2002;90:435-438.
10. Stevens TL, Burnett JC, Kinoshita M, et al. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest. 1995; 95:1101-1108.
11. Full Prescribing Information for NATRECOR (nesiritide), Scios Inc., 2001.
12. Maisel A, Cremo R, Gardetto N. The effects of nesiritide on serum levels of B-type natriuretic peptide (BNP) in patients admitted for decompensated congestive heart failure [abstract]. J Card Fail. 2002;(suppl):S49.
13. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
14. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
15. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA. 2002;287:1531-1540.
16. Silver M, Horton D, Ghali J, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
17. Peacock WF, Emerman CL, for the PROACTION Study Group. Safety and efficacy of nesiritide in observation patients. Presented at the 52nd Annual Scientific Session of the American College of Cardiology, March 30-April 2, 2003; Chicago, IL.
18. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens. 1996,9:432-436.
19. McCullough P, Philbin E, Spertus J, et al. Confirmation of a heart failure epidemic: Findings from the Resource Utilization Among Congestive Heart failure (REACH) study. J Am Coll Cardiol. 2002;39:60-69.
20. McCullough P. Cardiorenal risk. an important clinical intersection. Rev Cardiovasc Med. 2002;2:71-76.
21. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
22. Silverberg DS, Wexler D, Blum B, Iaina A. Anemia in chronic kidney disease and congestive heart failure. Blood Purif 2003;21:124-130.
23. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395-2401.
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
25. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
26. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
28. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA. 2002;287:1541-1547.
29. Fonarow G, Adams K, Abraham W. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: Analysis of 33,046 patients in the ADHERE Registry. J Cardiac Fail. In press, 2003,
30. Krumholz HM, Chen YT, Wang Y, et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72-77.
31. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
32. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003; 9:13-25.
33. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000; 85:1110-1113.
34. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987; 31:1402-1415.
35. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003; 294:F1115-F1119.
36. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
37. Goy W, Oliver PM, Purdy KF, et al. Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem J. 2001;358:379-387.
38. Brunner-La Rocca HP, Woods RL, Kaye DM, et al. Divergent effects of ANP and BNP in acute heart failure: Evidence for a putative BNP-selective receptor? J Hypertens. 2002,20:1195-1201.
39. Kishimoto, I, Hamra FK, Garbers DL. Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. Can J Physiol Pharmacol. 2001;79:715-722.
40. Chen H, Boerrigter G, Catalliotti A, et al. The Cardiac Peptide BNP and the Renally Derived Peptide Urodilatin Are Superior to ANP in Enhancing Renal Function in Overt Experimental CHF. In: J Card Fail, Heart Failure Society of America, Boca Raton, FL, 2002.
41. Chinkers M. Regulation of the atrial natriuretic peptide receptor guanylyl cyclase. Proc Soc Exp Biol Med. 1996,213:105-108.
42. Stevens TL, Rasmussen TE, Wei CM, et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail. 1996,2:119-125.
43. Cermak R, Kleta R, Forssmann WG, Schlatter E. Natriuretic peptides; increase a K+ conductance in rat mesangial cells. Pflugers Arch. 1996;431:571-577.
44. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: Mechanisms of action in coronary conductance and resistance arteries. Am J Physiol. 1999;276:H1049-H1057.
45. Kos T, Pacher R, Wimmer A, et al. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Wien Klin Wochenschr. 1998;110:89-95.
46. Beltowski J, Wojcicka G. Regulation of renal tubular sodium transport by cardiac natriuretic peptides: Two decades of research. Med Sci Monit. 2002;8:RA39-52.
47. Mistry SK, Chatterjee PK, Weerackody RP, et al. Evidence for atrial natriuretic factor induced natriuretic peptide receptor subtype switching in rat proximal tubular cells during culture. Exp Nephrol. 2001;6:104-111.
48. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clinic Proceedings. 2001;76:1111-1119.
49. Ishizaka Y, Yamamoto Y, Fukunaga, T, et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994;24:461-472.
50. Ishikura F, Ando Y, Park YD, et al. Changes of plasma atrial and brain natriuretic peptide levels during hemodialysis. Ren Fail. 1996;18:261-270.
51. Akiba T, Tachibana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44(suppl 1):S61-64.
52. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
53. Lee SW, Song JH, Kim GA, et al. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis. 2003;41:1257-1266.
54. McCullough P, Sandberg K. B-type natriuretic peptide and renal disease. Heart Fail Rev. In press, 2003.
55. Emerman C, et al. Nesiritide added to standard care results in favorable reduction in systolic blood pressure and heart rate compared to standard care alone. J Card Fail. 2003;9:S61.
56. Mathur V, Butler J, Emerman C, Young J. Efficacy of B-Type Natriuretic Peptide (BNP) in Patients with Renal Insufficiency and Acute Heart Failure: Results from the VMAC Trial. J Am Soc Nephrol. 2002;13:442A.
57. Butler J, Emerman C, Mathur V. Nephrol Dial Transplant. In press.
58. Seta K, Hayashi T, Sugawara A, et al. Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure. Ren Fail. 1998;20:717-723.
59. Mathur V, Joseph K. Use of nesiritide (B-type natriuretic peptide) as a bHidge to urgent "mIddle-of-the-night" hemodialysis. J Am Soc Nephrol. 2003;14:494-495A.
60. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: A continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991;115:360-366.
61. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
62. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
63. Jensen KF, Eiskjaer H, Carstens J, Pedersen EB Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond). 1999;96:5-15.
64. Mathur V. Use of Nesiritide (NES) for Treatment of Acute Renal Failure (ARF) Due to Decompensated Congestive Heart Failure (CHF). Am Soc Nephrol. 2002 Annual Meeting Online Publications 2002, Publication 111.
65. Tann S. B-Natriuretic Peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery International Heart Lung Transplant Meeting. Vienna, Austria, 2003.
66. Suganami T, Mukoyama M, Sugawara A, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol. 2001;12:2652,2663.
67. Kasahara M, Mukoyama M, Sugawara A, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000;11:1691-1701.
68. Yancy CW, Saltzberg M, Berkowitz RL, et al. Management of patients with congestive heart failure after hospitalization: Results from the Follow Up Serial Infusion of Nesiritide (FUSION) trial. J Card Fail. 2003;5(supplement):S11 (Abstract 034).
69. Burger AJ, Elkayam. U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35-39.
70. Roden R. Inotropic Effect of Human B-Type Natriuretic Peptide in the Failing Human Heart J Card Fail. 1998;4:19.
71. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation. 2003;107:2697-2701.